美国儿童多发性硬化症中新疾病修饰疗法的使用情况
本研究为队列研究,纳入美国12个儿科多发性硬化症中心随访的1019例儿童多发性硬化症(MS,n=748)或临床孤立综合征(CIS,n=271)患者,分析18岁前使用新疾病修饰疗法(DMT)的情况。结果显示,42%的患者至少使用过一种新DMT,且近10年使用率增加,尤其在≥12岁组;新DMT的短期副作用与成人报告相似。
要点
- 78%的MS患儿和11%的CIS患儿在18岁前接受过DMT。
- 42%的患者至少使用过一种新DMT,最常用为富马酸二甲酯(n=102)和那他珠单抗(n=101)。
- 新DMT的短期副作用与成人报告无差异。
核心结论
- 新DMT在儿童MS中经常使用,其短期安全性、耐受性和副作用与成人相似。
- 这些发现可能有助于为儿童MS管理提供信息。
研究设计与样本
- 队列研究,纳入美国儿科MS中心网络12个门诊实践点随访的MS或CIS患儿。
- 截至2017年7月,共纳入1019例患者(MS n=748,CIS n=271),65%为女性,平均发病年龄13.0±3.9岁,平均随访3.5±3.1年,中位每年就诊1.6次。
主要发现
- 78%(n=587)的MS患者和11%(n=31)的CIS患者在18岁前接受过DMT。
- 42%的患者至少使用过一种新DMT,包括富马酸二甲酯(n=102)、那他珠单抗(n=101)、利妥昔单抗(n=57)、芬戈莫德(n=37)、达克珠单抗(n=5)和特立氟胺(n=3)。
- 17%的患者初始DMT为新药(富马酸二甲酯36例、那他珠单抗30例、利妥昔单抗22例、芬戈莫德14例、特立氟胺2例)。
- 过去10年新药使用增加,尤其在≥12岁组,<12岁组增加程度较低。
- 新DMT的短期副作用与成人报告无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the use and safety of newer disease-modifying therapies (DMTs) in children with multiple sclerosis (MS) and clinically isolated syndrome (CIS) treated under 18 years of age. METHODS: This is a cohort study including children with MS or CIS followed at 12 outpatient practices participating in the US Network of Pediatric MS Centers. DMT use, including duration, dose, and side effects, was analyzed. Newer DMTs were defined as agents receiving Food and Drug Administration approval or with increased use in adult MS after 2005. RESULTS: As of July 2017, 1,019 pediatric patients with MS (n = 748) or CIS (n = 271) were enrolled (65% female, mean onset 13.0 ± 3.9 years, mean follow-up 3.5 ± 3.1 years, median 1.6 visits per year). Of these, 78% (n = 587) with MS and 11% (n = 31) with CIS received DMT before 18 years of age. This consisted of at least one newer DMT in 42%, including dimethyl fumarate (n = 102), natalizumab (n = 101), rituximab (n = 57), fingolimod (n = 37), daclizumab (n = 5), and teriflunomide (n = 3). Among 17%, the initial DMT prescribed was a newer agent (36 dimethyl fumarate, 30 natalizumab, 22 rituximab, 14 fingolimod, 2 teriflunomide). Over the last 10 years, the use of newer agents has increased, particularly in those ≥12 years and to lesser extent in those <12 years. The short-term side effect profiles of newer DMTs did not differ from those reported in adults. CONCLUSION: Newer DMTs are often used in pediatric MS, and have similar short-term safety, tolerability, and side effect profiles as in adults. These findings may help inform pediatric MS management.
引用
- Krysko KM, Graves J, Rensel M, et al. Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US. Neurology. 2018. PMID: 30333163. doi:10.1212/WNL.0000000000006471
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。